In a cohort of persons living with HIV in Hong Kong, surrogate virus neutralization testing for COVID-19 yielded a median level of 89% after the third dose of an inactivated COVID-19 vaccine, compared with 37% after the second dose. These results support using a 3-dose primary series for enhanced immune protection.
Keywords: COVID-19; HIV/AIDS; Hong Kong; SARS-CoV-2; inactivated vaccine; persons living with HIV; respiratory infections; severe acute respiratory syndrome coronavirus 2; vaccines; viruses; zoonoses.